For example, breast cancer patients with concomitant expression of Plk1 and the Estrogen Receptor (ER+) have a significantly worse relapse-free survival (RFS) index when compared to ER+ patients that have little or no Plk1 expression. Here, ESR1 is linked to breast cancer.